Disc Medicine Inc Sustainability Reports
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for serious hematologic diseases. The company targets fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00W9MJL04
2 reports from 2022 to 2023
Company Profile
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for serious hematologic diseases. The company targets fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
